Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01397)
Name
Risdiplam
Synonyms    Click to Show/Hide the Synonyms of This API
Risdiplam; 1825352-65-5; RG7916; RG-7916; UNII-76RS4S2ET1; RO7034067; 76RS4S2ET1; RO-7034067; 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one; 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one; Evrysdi; Risdiplam [INN]; Evrysdi (TN); Risdiplam [USAN]; Risdiplam; RG7916; Risdiplam [USAN:INN]; Risdiplam (JAN/USAN/INN); CHEMBL4297528; SCHEMBL17260852; GTPL11170; AMY23728; EX-A2074; MFCD31657372; WHO 10614; compound 1 [PMID: 30044619]; DB15305; RG7916;RO7034067; HY-109101; CS-0039501; D11406; Q48969152; CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CCNC2(CC2)C1; 4H-Pyrido(1,2-a)pyrimidin-4-one, 7-(4,7-diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-; 7-(4,7-Diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one
Clinical Status
Approved
PubChem CID
118513932
Formula
C22H23N7O
Canonical SMILES
CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
InChI
1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3
InChIKey
ASKZRYGFUPSJPN-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=118513932"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 401.5 Topological Polar Surface Area 78.1
XlogP 0.5 Complexity 886
Heavy Atom Count 30 Rotatable Bond Count 2
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 6
Full List of Drug Formulations (DFMs) Containing This API
          Risdiplam 0.75 mg/ml powder Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Ascorbic Acid; Disodium Edetate Dihydrate; Isomalt; Mannitol; Polyethylene Glycol 6000; Sodium Benzoate; Strawberry Flavor; Sucralose; Tartaric Acid
                   Dosage Form Powder
                   Company Genentech
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sucralose DIG Info Carbonic anhydrase II (Ki = 300 nM) [1]
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [2]
Sodium benzoate DIG Info Carbonic anhydrase II (Ki = 30000 nM) [3]
Isomalt DIG Info Colon cancer Caco-2 cells (EC50 = 99390 nM) [4]
Ascorbic acid DIG Info Albendazole monooxygenase (IC50 = 4.1 mg.mL-1) [5]
Polyethylene glycol 6000 DIG Info Albendazole monooxygenase (Inhibition ratio < 70 %) [5]
References
1 Sweet Binders: Carbonic Anhydrase IX in Complex with Sucralose. ACS Med Chem Lett. 2018 May 10; 9(7):657-661.
2 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
3 Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1; 15(3):573-8.
4 Novel natural compounds from endophytic fungi with anticancer activity. Eur J Med Chem. 2018 Aug 5; 156:316-343.
5 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.